HHPR
Latest Information Update: 26 Mar 2023
At a glance
- Originator HaiHe Biopharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 13 Mar 2023 HHPR is available for licensing as of 13 Mar 2023. https://www.haihepharma.com/en/cooperation (HaiHe Biopharma website, March 2023)
- 13 Mar 2023 Early research in Solid tumours in China (unspecified route) (HaiHe Biopharma pipeline, March 2023)